Claims
- 1. A genetic immunization method for inducing an antigen-specific immune response, comprising: a nucleic acid sequence encoding a peptide containing at least one antigenic determinant, operatively linked to one or more control sequences such that the nucleic acid sequence is expressed in a host cell, wherein the nucleic acid sequence is optionally formulated into a particle by complexation with one or more polymers, and wherein the nucleic acid is delivered to a vertebrate host cell.
- 2. The method of claim 1, wherein the host cell is a lymphoid cell.
- 3. The method of claim 2, wherein the host cell is a gut-associated lymphoid cell.
- 4. The method of claim 2, wherein the host cell is a nasal lymphoid cell.
- 5. The method of claim 1, wherein the delivery step is through intravascular administration.
- 6. The method of claim 1, wherein the delivery step is through oral administration.
- 7. The method of claim 1, wherein the nucleic acid is further protected by a coating.
- 8. The method of claim 7, wherein the coating is an enteric coating.
- 9. The method of claim 8, wherein the coated nucleic acid is orally delivered.
- 10. The method of claim 1, wherein the sequence is a DNA sequence.
- 11. The method of claim 10, wherein the DNA sequence is a plasmid.
- 12. The method of claim 1, wherein the host is a mammal.
- 13. A genetic immunization composition formulated for inducing an antigen-specific immune response, comprising: a nucleic acid sequence encoding a peptide containing at least one antigenic determinant, operatively linked to one or more control sequences such that the nucleic acid sequence is expressible in a host cell, wherein the nucleic acid sequence is optionally formulated into a particle by complexation with a polymer, for delivery to a vertebrate host cell.
- 14. The composition of claim 13, wherein the host cell is a lymphoid cell.
- 15. The composition of claim 14, wherein the host cell is a gut-associated lymphoid cell.
- 16. The composition of claim 14, wherein the host cell is a nasal lymphoid cell.
- 17. The composition of claim 13, wherein the delivery step is through intravascular administration.
- 18. The composition of claim 13, wherein the delivery step is through oral administration.
- 19. The composition of claim 13, wherein the nucleic acid is further protected by a coating.
- 20. The composition of claim 19, wherein the coating is an enteric coating.
- 21. The composition of claim 20, wherein the coated nucleic acid is orally delivered.
- 22. The composition of claim 13, wherein the sequence is a DNA sequence.
- 23. The composition of claim 22, wherein the DNA sequence is a plasmid.
- 24. The composition of claim 13, wherein the host is a mammal.
- 25. A method for generating an antibody response in a vertebrate host comprising of administering a nucleic acid encoding an antigen, the nucleic acid optionally being complexed to a polymer, in an amount sufficient to induce the desired immune response directed against the expressed antigen.
- 26. A method for generating a cellular immune response in a vertebrate host comprising of administering a nucleic acid encoding an antigen, the nucleic acid optionally being complexed to a polymer, in an amount sufficient to induce the desired immune response directed against the expressed antigen.
- 27. A method for generating an immune response in a vertebrate host, comprising: administering a nucleic acid encoding an antigen, the nucleic acid optionally being complexed to a polymer, in an amount sufficient to induce the desired immune response directed against the expressed antigen, and the nucleic acid is delivered to the intestinal lumen.
- 28. A method for determining the presence of a genetic immune response in a vertebrate, wherein the antigen is produced in a second vertebrate following nucleic acid delivery.
- 29. A method for determining the presence of a genetic immune response in a vertebrate, wherein the antigen is produced in a cell line following nucleic acid delivery.
- 30. A method for determining the presence of a genetic immune response in a vertebrate, wherein the antigen is produced in a primary cell culture following nucleic acid delivery.
- 31. A kit for genetic immunization, the kit comprising a transfection complex for in vivo gene transfer.
- 32. A kit for the detection of a genetic immune response, the kit comprising a transfection complex for in vitro gene transfer.
- 33. A kit for genetic immunization and detection of a genetic immune response, the kit comprising transfection complexes for in vivo and in vitro gene transfer.
Parent Case Info
[0001] This application is related to U.S. Provisional Application Serial No. 60/248,275 filed Nov. 14, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60248275 |
Nov 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09450315 |
Nov 1999 |
US |
Child |
09992957 |
Nov 2001 |
US |